Pyothorax-associated lymphoma (PAL) develops from a pyothorax caused by an artificial pneumothorax created during the treatment of pulmonary tuberculosis or tuberculous pleuritis. We report the first case of Epstein-Barr virus (EBV)-positive PAL arising from a posttraumatic empyema. A 75-year-old woman with chronic posttraumatic empyema presented with a tumor, which was connected to the wall of a pyothorax in the right thoracic cavity. She had a history of trauma to the right chest, which had occurred at the age of 45 years and had caused the chronic posttraumatic empyema. Pathological features of the resected tumor were conclusive for a diagnosis of EBV-positive PAL. Although neither postoperative chemotherapy nor radiotherapy was performed, remission was maintained for 3 years until recurrence in the liver. Combination chemotherapy led to complete remission, and 9 years after the initial diagnosis of PAL, the patient is still alive. An intriguing finding is the phenotypic alteration during the disease course. Although the primary tumor was negative for CD20 and CD3, the recurrent tumor expressed both of these molecules. We discuss this case of PAL, which was not a complication of lung tuberculosis, and the aberrant chronological phenotypic change observed in the lymphoma cells, and compare it with a usual case of PAL.

1.
Chan JKC, Aozasa K, Gaulard P: DLBCL associated with chronic inflammation; in Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds): WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press, 2008, pp 245-246.
2.
Iuchi K, Ichimiya A, Akashi A, Mizuta T, Lee YE, Tada H, Mori T, Sawamura K, Lee YS, Furuse K, Yamamoto S, Aozasa K: Non-Hodgkin's lymphoma of the pleural cavity developing from long-standing pyothorax. Cancer 1987;60:1771-1775.
3.
Iuchi K, Aozasa K, Yamamoto S, Mori T, Tajima K, Minato K, Mukai K, Komatsu H, Tagaki T, Kobashi Y, Yamabe H, Shimoyama M: Non-Hodgkin's lymphoma of the pleural cavity developing from long-standing pyothorax. Summary of clinical and pathological findings in thirty-seven cases. Jpn J Clin Oncol 1989;19:249-257.
4.
Aozasa K, Ohsawa M, Iuchi K, Tajima K, Komatsu H, Shimoyama M: Artificial pneumothorax as a risk factor for development of pleural lymphoma. Jpn J Cancer Res 1993;84:55-57.
5.
Aozasa K: Pyothorax-associated lymphoma. Int J Hematol 1996;65:9-16.
6.
Nakatsuka S, Yao M, Hoshida Y, Yamamoto S, Iuchi K, Aozasa K: Pyothorax-associated lymphoma: a review of 106 cases. J Clin Oncol 2002;20:4255-4260.
7.
Aozasa K, Takakuwa T, Nakatsuka S: Pyothorax-associated lymphoma: a lymphoma developing in chronic inflammation. Adv Anat Pathol 2005;12:324-331.
8.
Aozasa K: Pyothorax-associated lymphoma. J Clin Exp Hematopathol 2006;46:5-10.
9.
Kanno H, Yasunaga Y, Iuchi K, Yamauchi S, Tatekawa T, Sugiyama H, Aozasa K: Interleukin-6-mediated growth enhancement of cell lines derived from pyothorax-associated lymphoma. Lab Invest 1996;75:167-173.
10.
Kanno H, Naka N, Yasunaga Y, Iuchi K, Yamauchi S, Hashimoto M, Aozasa K: Production of the immunosuppressive cytokine interleukin-10 by Epstein-Barr-virus-expressing pyothorax-associated lymphoma: possible role in the development of overt lymphoma in immunocompetent hosts. Am J Pathol 1997;150:349-357.
11.
Kanno H, Aozasa K: Mechanism for the development of pyothorax-associated lymphoma. Pathol Int 1998;48:653-664.
12.
Petitjean B, Jardin F, Joly B, Martin-Garcia N, Tilly H, Picquenot JM, Brière J, Danel C, Mehaut S, Abd-Al-Samad I, Copie-Bergman C, Delfau-Larue MH, Gaulard P: Pyothorax-associated lymphoma: a peculiar clinicopathologic entity derived from B cells at late stage of differentiation and with occasional aberrant dual B- and T-cell phenotype. Am J Surg Pathol 2002;26:724-732.
13.
Androulaki A, Drakos E, Hatzianastassiou D, Vgenopoulou S, Gazouli M, Korkolopoulou P, Patsouris E, Dosios T: Pyothorax-associated lymphoma (PAL): a Western case with marked angiocentricity and review of the literature. Histopathology 2004;44:69-76.
14.
Hongyo T, Kurooka M, Taniguchi E, Iuchi K, Nakajima Y, Aozasa K, Nomura T: Frequent p53 mutations at dipyrimidine sites in patients with pyothorax-associated lymphoma. Cancer Res 1998;58:1105-1107.
15.
Schaue D, Kachikwu EL, McBride WH: Cytokines in radiobiological responses: a review. Radiat Res 2012;178:505-523.
16.
Schaue D, Micewicz ED, Ratikan JA, Xie MW, Cheng G, McBride WH: Radiation and inflammation. Semin Radiat Oncol 2015;25:4-10.
17.
Zhang T, Fu Q, Gao D, Ge L, Sun L, Zhai Q: EBV-associated lymphomas in 2008 WHO classification. Pathol Res Pract 2014;210:69-73.
18.
Narimatsu H, Ota Y, Kami M, Takeuchi K, Suzuki R, Matsuo K, Matsumura T, Yuji K, Kishi Y, Hamaki T, Sawada U, Miyata S, Sasaki T, Tobinai K, Kawabata M, Atsuta Y, Tanaka Y, Ueda R, Nakamura S: Clinicopathological features of pyothorax-associated lymphoma; a retrospective survey involving 98 patients. Ann Oncol 2007;18:122-128.
19.
Fukuno K, Tsurumi H, Kanemura N, Nishio M, Tanabashi S, Okamoto K, Moriwaki H: CD20-negative pyothorax-associated B cell lymphoma. Acta Haematol 2005;113:144-145.
20.
Tomita S, Mori KL, Sakajiri S, Oshimi K: B-cell-marker-negative (CD7+, CD19-) Epstein-Barr virus-related pyothorax-associated lymphoma with rearrangement in the JH gene. Leuk Lymphoma 2003;44:727-730.
21.
Yamamoto T, Masuda A, Sawada T, Nishikawa T, Yoshinaga K, Kazama H, Motoji T, Nakamura N, Kobayashi M: Pyothorax-associated lymphoma: a case showing transition from T-cell-rich polymorphic lesion to diffuse large B-cell lymphoma. Pathol Res Pract 2007;203:605-611.
22.
al Saati T, Delécluze HJ, Chittal S, Brousset P, Magaud JP, Dastugue N, Cohen-Knafo E, Laurent G, Rubin B, Delsol G: A novel human lymphoma cell line (Deglis) with dual B/T phenotype and gene rearrangements and containing Epstein-Barr virus genomes. Blood 1992;80:209-216.
23.
Mori N, Yatabe Y, Narita M, Kobayashi T, Asai J: Pyothorax-associated lymphoma. An unusual case with biphenotypic character of T and B cells. Am J Surg Pathol 1996;20:760-766.
24.
Daibata M, Taguchi T, Nemoto Y, Saito T, Machida H, Imai S, Miyoshi I, Taguchi H: Epstein-Barr virus (EBV)-positive pyothorax-associated lymphoma (PAL): chromosomal integration of EBV in a novel CD2-positive PAL B-cell line. Br J Haematol 2002;117:546-557.
25.
Nakamichi I, Takakuwa T, Tanio Y, Iuchi K, Aozasa K: Pyothorax-associated lymphoma: an unusual case with both T- and B-cell genotypes. Virchows Arch 2005;447:888-891.
26.
Wang E, Stoecker M: Primary mediastinal (thymic) large B cell lymphoma with aberrant expression of CD3: a case report with review of the literature. Int J Hematol 2010;91:509-515.
27.
Oliveira JL, Grogg KL, Macon WR, Dogan A, Feldman AL: Clinicopathologic features of B-cell lineage neoplasms with aberrant expression of CD3: a study of 21 cases. Am J Surg Pathol 2012;36:1364-1370.
28.
Kanno H, Ohsawa M, Iuchi K, Nakatsuka S, Yamamoto S, Nishioka M, Aozasa K: Appearance of a different clone of Epstein-Barr virus genome in recurrent tumor of pyothorax-associated lymphoma (PAL) and a mini-review of PAL. Leukemia 1998;12:1288-1294.
29.
Nakatsuka S, Nishiu M, Tomita Y, Miwa H, Takakuwa T, Iuchi K, Yamamoto S, Aozasa K: Enhanced expression of neuron-specific enolase (NSE) in pyothorax-associated lymphoma (PAL). Jpn J Cancer Res 2002;93:411-416.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.